StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Axsome Therapeutics's EV/EBITDA was 4.0× on Jul 31, 2018, against 2.6× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2018Jul 31, 20184.0×+0.1
2017Dec 29, 20173.9×−0.2
2016Dec 30, 20164.1×–

More Axsome Therapeutics figures

See a number that looks wrong?